ORASONE

Clinical safety rating: caution

Comprehensive clinical and safety monograph for ORASONE (ORASONE).

How it works

Orasone (prednisone) is a corticosteroid that binds to the glucocorticoid receptor, leading to modulation of gene expression and suppression of inflammatory cytokines, immune response, and adrenal function.

What the body does with it

Metabolism	Primarily hepatic via CYP3A4; also undergoes 11-beta-hydroxysteroid dehydrogenase interconversion with prednisolone.
Excretion	Primarily renal: ~80% as 17-keto metabolites and unchanged drug; biliary/fecal excretion accounts for <10%.
Half-life	Terminal half-life of 3-4 hours for prednisolone (active metabolite of ORASONE); clinically, duration of HPA-axis suppression is more relevant (12-36 hours) with longer effects at higher doses.
Protein binding	Prednisolone: 70-90% bound to transcorrin (corticosteroid-binding globulin) and albumin; binding decreases with higher doses (saturable).
Volume of Distribution	Vd: 0.4-0.6 L/kg for prednisolone; indicates distribution into total body water and peripheral tissues.
Bioavailability	Oral: 70-90% (fasting); IM: 100% (systemic); bioavailability is dose-dependent due to saturable protein binding.
Onset of Action	Oral: 1-2 hours; IM: 1-2 hours; IV: immediate (within 5 min) [anti-inflammatory effect]. Clinical effect may be delayed.
Duration of Action	Duration of anti-inflammatory effect: 12-36 hours after single dose; HPA-axis suppression may persist for 24-48 hours after short-term use.

Classification & Brands

Dosing & administration

Adults: 5-60 mg orally once daily or divided twice daily; typical starting dose 5-40 mg/day. Route: oral. Frequency: once daily or every 12 hours.

Dosage form	TABLET
Renal impairment	No dosage adjustment required for GFR ≥30 mL/min; for GFR <30 mL/min, consider dose reduction by 25% and monitor for fluid retention.
Liver impairment	Child-Pugh A: no adjustment; Child-Pugh B: reduce dose by 50%; Child-Pugh C: reduce dose by 75% or use alternative.
Pediatric use	0.1-2 mg/kg/day orally once daily or divided every 12-24 hours; maximum 60 mg/day.
Geriatric use	Start at lowest effective dose (e.g., 5 mg/day), increase slowly; monitor for osteoporosis, hyperglycemia, and fluid retention.

Use during pregnancy

1st trimester	Consult provider
2nd trimester	Consult provider
3rd trimester	Consult provider

Clinical note

Comprehensive clinical and safety monograph for ORASONE (ORASONE).

Breastfeeding	Excreted in breast milk; M/P ratio approximately 0.5-1.0. At maternal doses >20 mg/day, monitor infant for adrenal suppression; avoid high-dose or prolonged therapy; consider risk-benefit.
Teratogenic Risk	FDA Pregnancy Category D. First trimester: increased risk of cleft palate (odds ratio 3-4), oral cleft; second/third trimester: fetal adrenal suppression, intrauterine growth restriction, premature birth; chronic use associated with premature rupture of membranes.
Fetal Monitoring

Warnings & precautions

■ FDA Black Box Warning

None explicitly listed; however, long-term use carries risks of adrenal suppression, osteoporosis, and increased susceptibility to infections. Avoid abrupt cessation after prolonged therapy.

Side Effect Profile

Serious Effects

Absolute Contraindications

["Systemic fungal infections","Hypersensitivity to prednisone or any component","Live or attenuated vaccine administration","Idiopathic thrombocytopenic purpura (ITP) (relative)","Pregnancy (relative, use only if clearly needed)","Lactation (use with caution)"]

Clinical Precautions

Precautions

["Adrenal suppression with prolonged use or high doses","Increased risk of infections","Osteoporosis with long-term use","Gastrointestinal perforation or bleeding","Cushing's syndrome","Growth suppression in children","Myopathy","Ocular effects (cataracts, glaucoma)","Psychiatric disturbances","Thrombotic events"]

Clinical Tips & Counseling

Drug interactions

Loading safety data…

ORASONE

Clinical safety rating: caution

Comprehensive clinical and safety monograph for ORASONE (ORASONE).

How it works

What the body does with it

Metabolism	Primarily hepatic via CYP3A4; also undergoes 11-beta-hydroxysteroid dehydrogenase interconversion with prednisolone.
Excretion	Primarily renal: ~80% as 17-keto metabolites and unchanged drug; biliary/fecal excretion accounts for <10%.
Half-life	Terminal half-life of 3-4 hours for prednisolone (active metabolite of ORASONE); clinically, duration of HPA-axis suppression is more relevant (12-36 hours) with longer effects at higher doses.
Protein binding	Prednisolone: 70-90% bound to transcorrin (corticosteroid-binding globulin) and albumin; binding decreases with higher doses (saturable).
Volume of Distribution	Vd: 0.4-0.6 L/kg for prednisolone; indicates distribution into total body water and peripheral tissues.
Bioavailability	Oral: 70-90% (fasting); IM: 100% (systemic); bioavailability is dose-dependent due to saturable protein binding.
Onset of Action	Oral: 1-2 hours; IM: 1-2 hours; IV: immediate (within 5 min) [anti-inflammatory effect]. Clinical effect may be delayed.
Duration of Action	Duration of anti-inflammatory effect: 12-36 hours after single dose; HPA-axis suppression may persist for 24-48 hours after short-term use.

Classification & Brands

Dosing & administration

Adults: 5-60 mg orally once daily or divided twice daily; typical starting dose 5-40 mg/day. Route: oral. Frequency: once daily or every 12 hours.

Dosage form	TABLET
Renal impairment	No dosage adjustment required for GFR ≥30 mL/min; for GFR <30 mL/min, consider dose reduction by 25% and monitor for fluid retention.
Liver impairment	Child-Pugh A: no adjustment; Child-Pugh B: reduce dose by 50%; Child-Pugh C: reduce dose by 75% or use alternative.
Pediatric use	0.1-2 mg/kg/day orally once daily or divided every 12-24 hours; maximum 60 mg/day.
Geriatric use	Start at lowest effective dose (e.g., 5 mg/day), increase slowly; monitor for osteoporosis, hyperglycemia, and fluid retention.

Use during pregnancy

1st trimester	Consult provider
2nd trimester	Consult provider
3rd trimester	Consult provider

Clinical note

Comprehensive clinical and safety monograph for ORASONE (ORASONE).

Breastfeeding	Excreted in breast milk; M/P ratio approximately 0.5-1.0. At maternal doses >20 mg/day, monitor infant for adrenal suppression; avoid high-dose or prolonged therapy; consider risk-benefit.
Teratogenic Risk	FDA Pregnancy Category D. First trimester: increased risk of cleft palate (odds ratio 3-4), oral cleft; second/third trimester: fetal adrenal suppression, intrauterine growth restriction, premature birth; chronic use associated with premature rupture of membranes.
Fetal Monitoring

Warnings & precautions

■ FDA Black Box Warning

None explicitly listed; however, long-term use carries risks of adrenal suppression, osteoporosis, and increased susceptibility to infections. Avoid abrupt cessation after prolonged therapy.